"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
| Descriptor ID |
D020533
|
| MeSH Number(s) |
D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
|
| Concept/Terms |
Angiogenesis Inhibitors- Angiogenesis Inhibitors
- Neovascularization Inhibitors
- Angiogenic Antagonists
- Angiogenic Inhibitors
- Angiostatic Agents
- Agents, Angiostatic
- Antagonists, Angiogenic
- Anti-Angiogenetic Agents
- Agents, Anti-Angiogenetic
- Anti Angiogenetic Agents
- Anti-Angiogenic Drugs
- Anti Angiogenic Drugs
- Drugs, Anti-Angiogenic
- Antiangiogenic Agents
- Agents, Antiangiogenic
- Inhibitors, Angiogenesis
- Inhibitors, Angiogenetic
- Inhibitors, Angiogenic
- Inhibitors, Neovascularization
- Angiogenetic Antagonists
- Antagonists, Angiogenetic
- Angiogenetic Inhibitors
Anti-Angiogenesis Effect- Anti-Angiogenesis Effect
- Anti Angiogenesis Effect
- Effect, Anti-Angiogenesis
- Antiangiogenesis Effect
- Effect, Antiangiogenesis
- Antiangiogenesis Effects
- Effects, Antiangiogenesis
- Anti-Angiogenesis Effects
- Anti Angiogenesis Effects
- Effects, Anti-Angiogenesis
|
Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".
This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 1 | 4 |
| 2002 | 5 | 1 | 6 |
| 2003 | 4 | 3 | 7 |
| 2004 | 3 | 4 | 7 |
| 2005 | 3 | 2 | 5 |
| 2006 | 6 | 2 | 8 |
| 2007 | 14 | 2 | 16 |
| 2008 | 11 | 2 | 13 |
| 2009 | 8 | 7 | 15 |
| 2010 | 11 | 5 | 16 |
| 2011 | 13 | 4 | 17 |
| 2012 | 11 | 4 | 15 |
| 2013 | 18 | 8 | 26 |
| 2014 | 11 | 14 | 25 |
| 2015 | 23 | 8 | 31 |
| 2016 | 11 | 7 | 18 |
| 2017 | 6 | 3 | 9 |
| 2018 | 12 | 10 | 22 |
| 2019 | 17 | 16 | 33 |
| 2020 | 12 | 14 | 26 |
| 2021 | 8 | 18 | 26 |
| 2022 | 1 | 16 | 17 |
| 2023 | 2 | 10 | 12 |
| 2024 | 19 | 11 | 30 |
| 2025 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.
-
Magrath G, Luvisi J, Russakoff D, Oakley J, Say EA, Blice J, Jayagopal A, Tucker S, Loayza A, Baker GH, Obeid JS. Use of a Convolutional Neural Network to Predict the Response of Diabetic Macular Edema to Intravitreal Anti-VEGF Treatment: A Pilot Study. Am J Ophthalmol. 2025 May; 273:176-181.
-
Kalavar M, Sridhar J. Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. Curr Opin Ophthalmol. 2025 May 01; 36(3):189-198.
-
Durrani AF, Chaudhary V, Garg SJ. Reducing rates of endophthalmitis from intravitreal injections - strategies and areas of controversy. Curr Opin Ophthalmol. 2025 May 01; 36(3):229-236.
-
Zhao CS, Chwialkowski K, Wai KM, Mruthyunjaya P, Rahimy E, Koo EB. Risk of Cataract Surgery Complications in Patients With Prior Intravitreal Injection Therapy. Am J Ophthalmol. 2025 04; 272:106-116.
-
Momenaei B, Yonekawa Y, Abril P, McCullough R, Abbey AM. Outcomes of Intravitreal Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Previously Treated With Faricimab. Ophthalmic Surg Lasers Imaging Retina. 2025 04; 56(4):206-211.
-
Swaminathan S, Mahmoudzadeh R, Wakabayashi T, Bowers M, Momenaei B, Abishek RM, Salabati M, Hsu J, Dunn JP. OUTCOMES OF PRO RE NATA VERSUS TREAT-AND-EXTEND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR MYOPIC MACULAR NEOVASCULARIZATION IN MULTIETHNIC PATIENTS IN THE UNITED STATES. Retina. 2024 12 01; 44(12):2057-2065.
-
Gonzales J, Acharya NR, Sugar EA, Burke AE, Vitale AT, Gupta V, Dunn JP, Lightman SL, Thorne JE, Kim RY, Yeh S, Altaweel MM, Kempen JH, Holbrook JT, Jabs DA. Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment. Ophthalmology. 2025 May; 132(5):527-537.
-
Clark AJ, Regillo C, Gune S, Pieramici DJ. Refillable Drug Reservoirs for Retinal Vascular Diseases. Am J Ophthalmol. 2025 Sep; 277:504-511.
-
Kaufmann GT, Boucher N, Sharma C, Aggarwal N, Starr MR. Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration. Am J Ophthalmol. 2025 Feb; 270:172-182.
-
Alsoudi AF, Wai KM, Koo E, Parikh R, Mruthyunjaya P, Rahimy E. Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2024 10 01; 142(10):972-975.